false 0001347242 0001347242 2023-11-28 2023-11-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 28, 2023 (November 21, 2023)

 

Lipella Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   005-93847   20-2388040
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

7800 Susquehanna St., Suite 505

Pittsburgh, PA

  15208
(Address of registrant’s principal executive office)   (Zip code)

   

Registrant’s telephone number, including area code: (412) 901-0315 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading Symbol(s)   Name of exchange on which
registered
Common Stock, par value $0.0001 per share   LIPO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

  

 

Item 3.01. Failure to Satisfy a Continued Listing Rule or Standard - Remediated

On November 21, 2023, Lipella Pharmaceuticals Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company may have failed to maintain a required minimum of $2,500,000 in stockholders’ equity for continued listing, as required under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”), based on the financial results reported in the Company’s Form 10-Q for the period ended September 30, 2023, as filed with the SEC on November 14, 2023. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), which will continue to trade uninterrupted on the Nasdaq Capital Market under the ticker “LIPO.”

If the Company does not demonstrate or regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting from the Nasdaq Capital Market.

 

The Company intends to continuously monitor the closing bid price for its Common Stock, and is in the process of considering various measures to resolve any alleged deficiency and regain compliance with the Minimum Equity Rule. However, there can be no assurance that the Company will be able to demonstrate or regain compliance with the Minimum Equity Rule, even if it maintains compliance with the other Nasdaq listing requirements, or that Nasdaq will grant the Company any extension of time to regain compliance with the Minimum Equity Rule or any other Nasdaq listing requirements, if applicable.

Cautionary Statement Regarding Forward-Looking Statements

 

This Current Report on Form 8-K (this “Form 8-K”) contains forward-looking statements. Such forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions, including those related to future compliance with the Minimum Equity Rule, which can be identified by terminology such as “may,” “will,” “expects,” “anticipates,” “aims,” “potential,” “future,” “intends,” “plans,” “believes,” “estimates,” “continue,” “likely to” and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company’s control, including risks related to the Company’s ability to regain compliance with Nasdaq listing standards, the Company’s ability to obtain an additional compliance period, if needed, the Company’s ability to take actions that may be required for its continued listing on Nasdaq, the Company’s current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this Form 8-K, except as required by applicable law.

 

  

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

             
        Lipella Pharmaceuticals Inc.
       
Date: November 28, 2023       By:   /s/ Jonathan Kaufman
            Jonathan Kaufman
            Chief Executive Officer
            (Principal Executive Officer)

 

 

  

 

v3.23.3
Cover
Nov. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 28, 2023
Entity File Number 005-93847
Entity Registrant Name Lipella Pharmaceuticals Inc.
Entity Central Index Key 0001347242
Entity Tax Identification Number 20-2388040
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7800 Susquehanna St.
Entity Address, Address Line Two  Suite 505
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15208
City Area Code (412)
Local Phone Number 901-0315
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol LIPO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Lipella Pharmaceuticals Charts.
Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Lipella Pharmaceuticals Charts.